cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Anaptysbio Inc
2 own
2 watching
Current Price
$0
$0.36
(1.5%)
logo-anab
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
678.79M
52-Week High
52-Week High
32.96
52-Week Low
52-Week Low
18.2
Average Volume
Average Volume
0.14M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
121.2182
iconMarket Capitalization678.79M
icon52-Week High32.96
icon52-Week Low18.2
iconAverage Volume0.14M
iconDividend Yield--
iconP/E Ratio121.2182
What does the Anaptysbio Inc do?
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Read More
How much money does Anaptysbio Inc make?
News & Events about Anaptysbio Inc.
Globe Newswire
18days ago
SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up ...
Globe Newswire
2 months ago
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer First-in-class pivotal data in endometrial cancer, if approved, to be a potential significant driver of...
Globe Newswire
3 months ago
Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancerCOSTAR, a Phase 2 trial of JEMPERLI plus cobolimab, an anti-TIM-3 antagonist antibody licensed to TESARO, Inc. (GSK) as part of the same ...
Globe Newswire
4 months ago
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James Jamie Topper, M.D., Ph.D...
Ticker Report
6 months ago
DekaBank Deutsche Girozentrale lifted its holdings in AnaptysBio, Inc. (NASDAQ:ANAB Get Rating) by 10.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The institutional investor owned 5,300 shares of the ...
Frequently Asked Questions
Frequently Asked Questions
What is Anaptysbio Inc share price today?
plus_minus_icon
Can Indians buy Anaptysbio Inc shares?
plus_minus_icon
How can I buy Anaptysbio Inc shares from India?
plus_minus_icon
Can Fractional shares of Anaptysbio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Anaptysbio Inc stocks?
plus_minus_icon
What is today’s traded volume of Anaptysbio Inc?
plus_minus_icon
What is today’s market capitalisation of Anaptysbio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Anaptysbio Inc?
plus_minus_icon
What percentage is Anaptysbio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Anaptysbio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.36
(1.5%)
logo-anab
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$12.38
$0.20 (1.64 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$12.42
$-0.40 (-3.12 %)
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
$21.27
$-0.02 (-0.09 %)
Provention Bio Inc
Provention Bio Inc
$8.58
$0.16 (1.90 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$12.38
$0.20 (1.64 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$12.42
$-0.40 (-3.12 %)
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
$21.27
$-0.02 (-0.09 %)
Provention Bio Inc
Provention Bio Inc
$8.58
$0.16 (1.90 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00